益生菌联合熊去氧胆酸治疗非酒精性脂肪性肝病疗效观察  

Effect of Probiotics Combined with Ursodeoxycholic Acid on Nonalcoholic Fatty Liver Disease

作　　者：王黎黎 WANG Lili(Chaoyang Central Hospital,Chaoyang 122000,China)

机构地区：[1]朝阳市中心医院,辽宁朝阳122000

出　　处：《中国医药指南》2022年第19期72-74,共3页Guide of China Medicine

摘　　要：目的观察益生菌联合熊去氧胆酸治疗非酒精性脂肪性肝病(NAFLD)疗效。方法选取我院2018年4月至2020年1月收治的89例NAFLD患者,按照随机数字表法分为试验组46例、对照组43例,试验组予以益生菌(双歧杆菌三联活菌胶囊)联合熊去氧胆酸治疗,对照组予以熊去氧胆酸治疗,观察治疗效果。结果试验组治疗总有效率为91.30%、对照组为74.41%,试验组显著高于对照组(P<0.05);治疗后,两组ALT、AST、GGT水平均显著降低,且试验组显著低于对照组(P<0.05);治疗后两组TC、TG水平均显著降低,且试验组显著低于对照组(P<0.05);试验组不良反应发生率为8.70%;对照组为4.65%,试验组不良反应发生率与对照组比较并无显著差异(P>0.05)。结论对NAFLD患者予以益生菌联合熊去氧胆酸治疗,能有效减轻疾病对患者肝脏的损害,有助于患者生存质量提高,且用药较为安全,治疗效果显著,患者较易接受。Objective To observe the efficacy of probiotics combined with ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease.Methods Eighty-nine patients with non-alcoholic fatty liver disease admitted in our hospital from April 2018 to January 2020 were divided into experimental group 46 cases and control group 43 cases according to random digital table method.The experimental group was treated with probiotics(live combined bifidobacterium)combined with ursodeoxycholic acid and the control group with ursodeoxycholic acid to observe the therapeutic effect.Results The total effective rate of the experimental group was 91.30%,the control group was 74.41%,and the experimental group was significantly higher than the control group(P<0.05);after treatment,the levels of ALT,AST and GGT in the two groups were significantly decreased,and the experimental group was significantly lower than the control group(P<0.05).The incidence of adverse reactions in the experimental group was 8.70%,and that in the control group was 4.65%.There was no significant difference in the incidence of adverse reactions between the experimental group and the control group(P>0.05).Conclusion The treatment of patients with non-alcoholic fatty liver disease with probiotics combined with ursodeoxycholic acid can effectively reduce the damage of the disease to the patient's liver,help improve the quality of life of the patients,and the medication is safer and the treatment effect is significant.

关 键 词：非酒精性脂肪性肝病 益生菌 熊去氧胆酸 不良反应 

分 类 号：R575.5[医药卫生—消化系统]